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Objectives. We sought to study the markers of lipid peroxida-
tion and defenses against oxidative stress in patients with varying
degrees of heart failure.
Background. Despite advances in other areas of cardiovascular
disease, the morbidity and mortality from congestive heart failure
(CHF) are increasing. Data mainly from animal models suggest
that free radical injury may promote myocardial decompensation.
However, there are no studies in humans correlating the severity
of heart failure with increased free radical injury and antioxi-
dants.
Methods. Fifty-eight patients with CHF and 19 control subjects
were studied. In addition to complete clinical and echocardio-
graphic evaluations, the prognosis of these patients was estab-
lished by measuring the levels of soluble tumor necrosis factor-
alpha receptors 1 and 2 (sTNF-R1 and sTNF-R2). Oxidative stress
was evaluated by measuring plasma lipid peroxides (LPO), mal-
ondialdehyde (MDA), glutathione peroxidase (GSHPx) and vita-
min E and C levels.
Results. The patients’ age range, cause of heart failure and drug
intake were comparable across the different classes of heart
failure. Heart failure resulted in a significant increase in LPO
(p < 0.005), MDA (p < 0.005), sTNF-R1 (p < 0.005) and sTNF-R2
(p < 0.005). There was a significant positive correlation between
the clinical class of heart failure and LPO, MDA, sTNF-R1 and
sTNF-R2 levels. There was an inverse correlation between GSHPx
and LPO. With increased lipid peroxidation in patients with CHF,
the levels of vitamin C decreased, but vitamin E levels were
maintained.
Conclusions. These data demonstrate a progressive increase in
free radical injury and encroachment on antioxidant reserves with
the evolution of heart failure; they also suggest that oxidative
stress may be an important determinant of prognosis. The ther-
apeutic benefit of administering antioxidant supplements to pa-
tients with CHF should be evaluated.
(J Am Coll Cardiol 1998;31:1352–6)
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Despite a remarkable decline in the death rate from cardio-
vascular disease over the past 30 years, both the morbidity and
mortality from congestive heart failure (CHF) have been
steadily increasing (1). There have been considerable advances
in our understanding of the functional alterations associated
with the early adaptive phases of myocardial hypertrophy and
the terminal stages of heart failure; however, critical questions
remain about the evolution of cardiac decompensation. Pres-
ently available therapeutic interventions have not been shown
to substantially improve the long-term survival of patients with
dilated cardiomyopathy and CHF. The underlying heart dis-
ease is relentlessly progressive in almost all patients who
develop symptoms of overt failure, and mortality continues to
be unacceptably high (2). Trying to enhance cardiac function
during the later stages of heart failure cannot be done over the
long term. The solution lies in defining and preventing the
causes of myocardial failure or arresting and reversing its
evolution.
Recent investigations suggest that free radicals may be
important contributors to the deterioration of the decompen-
sating myocardium (3,4). This finding is not surprising because
a number of factors associated with heart failure, such as
increased plasma catecholamines (5), cardiac sympathetic tone
(6), microvascular reperfusion injury (7,8), cytokine stimula-
tion (9,10) and mitochondrial deoxyribonucleic acid mutations
(11) (particularly complex I), are known stimuli for peroxida-
tive damage (12–14). Markers of oxidative stress, such as
elevated levels of breath pentane (15) or plasma and urinary
malondialdehyde (MDA) (16,17), have been reported. How-
ever, there are no studies in human CHF evaluating markers of
peroxidation, antioxidant levels, functional class and indexes of
prognosis.
In this study, we examined markers of lipid peroxidation
and oxidative defenses in patients with different degrees of
heart failure. Soluble tumor necrosis factor-alpha receptors 1
and 2 (sTNF-R1 and sTNF-R2), which have been shown to be
indexes of patient prognosis, were also measured to determine
the clinical severity of CHF. Our findings strongly support the
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adverse effects of free radicals in human CHF and suggest that
antioxidant supplements may be of therapeutic benefit.
Methods
Study group. Fifty-eight patients (43 men, 15 women) with
CHF and 19 control subjects (12 men, 7 women) were studied
(Table 1). Patients with recent cardiac events such as myocar-
dial infarction, those on dialysis, those with decompensated
liver disease or malignancy and those taking antioxidant vita-
min supplements were excluded. Control subjects were healthy
hospital staff volunteers of the same age and gender mix and
with no history of diabetes or lipid abnormalities. The Ethics
Committee of the University of Toronto approved the study
protocols; written informed consent was obtained from all
study participants.
Clinical assessment. A detailed clinical assessment was
done by one investigator (A.G.) using a standardized format.
The diagnosis of heart failure was confirmed in all patients by
clinical and noninvasive assessment of myocardial function.
Echocardiograms were available for detailed review in 48
patients. Left ventricular ejection fraction, left ventricular
end-systolic diameter and left ventricular end-diastolic diame-
ter were measured by one investigator (A.O.) who had no
knowledge of the clinical state or laboratory data. Previous
reproducibility studies performed in the Toronto Hospital
Echocardiography Laboratory have determined a retest vari-
ability (95% limits) of 3 mm in left ventricular end-diastolic
diameter.
Blood sampling. Immediately after the initial interview,
20 ml of blood was obtained by venipuncture and was centri-
fuged at 3,000 rpm at 4°C for 7 min (Sorval refrigerated
centrifuge, Sorval Instruments), and the plasma was separated
and stored in a frozen state at 220°C for analysis. All
measurements of lipid peroxide (LPO) were done within 1
month of drawing the blood. In separate experiments we found
that in 10 normal subjects, LPO levels measured on the same
day that the blood was drawn was 2.22 6 0.19 mmol/liter, and
after 1 month of storage in the conditions described previously,
the levels were unchanged at 2.22 6 0.20 mmol/liter.
Measurement of LPO. Lipid peroxides were measured
using a commercially available kit (Kamiya Biomedical Co.)
(18,19). Absorbance was measured spectrophotometrically at
675 nm using a Hitachi U2000 spectrophotometer.
Analysis of MDA. The procedure used was adapted from
that of Draper et al. (20,21). Briefly, samples were injected into
a high performance liquid chromatography column (Waters
C18) with the UV/Vis variable detector (Shimadzu, SPD-6) set
at 532 nm. An integrator (Shimadzu CR-3A) was connected to
the detector and net peak areas were calculated. 1,1,3,3-
Tetraethoxypropane (Sigma Co.) was used as the MDA stan-
dard.
Plasma tocopherols. Plasma vitamin E was analyzed by a
modification of the method of Bieri et al. (22). A reverse-phase
high pressure liquid chromatographic system (LC-6A, Shi-
madzu) with a C18 column was used for the separation of
tocopherols. The concentration of the vitamin in the sample
was calculated from the peak areas of standard and sample
curves. Although plasma vitamin E represents only a small
proportion of total body membrane-bound stores, nonfasting
plasma vitamin E, uncorrected for plasma lipoproteins, ap-
pears to be an excellent reflection of an individual’s actual
vitamin E level (23,24).
Glutathione peroxidase activity. The activity of the
selenium-dependent glutathione peroxidase (GSHPx) in
plasma was measured by using the coupled assay procedure of
Paglia and Valentine (25), as modified in our previous report
(26).
Vitamin C (ascorbic acid). The method used determines
the total biologically active vitamin C (L-ascorbic acid and
dehydro-L-ascorbic acid) colorimetrically (27). The color den-
sity was read at 521.0 nm against a reagent blank and com-
pared with a calibration curve of known standards.
Measurement of sTNF-R1 and sTNF-R2. Human sTNF-R1
(p55) and sTNF-R2 (p75) were measured in 61 patients, using
commercially available enzyme-linked immunosorbent assay
kits (Quantikine, R&D Systems). The standards were prepared
from 7.8 to 500 pg/ml for sTNF receptors. All samples were run
in duplicate.
Abbreviations and Acronyms
CHF 5 congestive heart failure
GSHPx 5 glutathione peroxidase
LPO 5 lipid peroxide
MDA 5 malondialdehyde
sTNF-R1 and -R2 5 soluble tumor necrosis factor
receptors 1 and 2
Table 1. Characteristics of Patients With Heart Failure
NYHA Functional
Class
No. of
Patients
Gender
(M/F)
Age
(years) Ejection Fraction (%)
I 9 6/3 63.7 6 7.5 40.6 6 5.8 (n 5 8)
II 19 13/6 54.6 6 2.44 33.5 6 3.1 (n 5 19)
III 18 15/3 60.0 6 4.6 25.1 6 2.4 (n 5 14)
IV 12 9/3 61.5 6 3.5 30.0 6 4.5 (n 5 8)
Data are presented as number of patients or mean value 6 SEM. F 5 female; M 5 male; NYHA 5 New York Heart
Association.
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Statistical analysis. Data are presented as the mean
value 6 SEM. The significance of the differences between
control subjects and patients in the different heart failure
classes was determined by the nonparametric Kruskal-Wallis
test. The relations of New York Heart Association functional
class heart failure to various variables of oxidative stress were
analyzed by the Spearman rank correlation. The differences in
age, the pattern of the drug intake and the comorbid condi-
tions among the different heart failure classes were tested
using the chi-square test.
Results
Clinical features. Age. The age distributions across the
heart failure classes were not significantly different (Table 1).
Causes of heart failure. The most common cause of heart
failure in these patients was ischemic heart disease, with the
second most common cause being idiopathic cardiomyopathy.
The distribution of the disease across different classes of heart
failure was not significant (chi-square 0.6662, df 12).
Comorbid conditions. The most frequent comorbid condi-
tions were diabetes, hypertension and hyperlipidemia. The
distribution of these comorbid conditions was not significantly
different among heart failure groups (chi-square 0.1144, df 21).
Only two patients smoked.
Medication intake. Review of the medications disclosed
that the majority of the patients were taking angiotensin-
converting enzyme inhibitors and diuretic agents. A significant
number of patients were also taking digoxin and aspirin (Table
2). The intake of angiotensin-converting enzyme inhibitor,
acetylsalicylic acid, furosemide, beta-blockers, inotropic agents
and amiodarone was not significantly different between the
heart failure groups.
Markers of oxidative stress and their relation to heart
failure. LPO and heart failure. The LPO levels were signifi-
cantly different between control subjects and patients with
CHF (p , 0.005). There was a significant relation between the
patients’ LPO levels and functional class (rs 5 0.75, p , 0.01)
(Fig. 1).
MDA and heart failure. The MDA levels were significantly
different between control subjects and patients with CHF (p ,
0.005). There was a significant relation beween the patients’
MDA levels and functional class (rs 5 0.37, p , 0.01) (Fig. 2).
LPO in relation to cardiac function. In contrast to the
relation of oxidative variables to functional class, there were no
statistically significant correlations between LPO and ejection
fraction or left ventricular function or dimensions as deter-
mined by echocardiography.
Antioxidant levels. GSHPx. The levels of this enzyme var-
ied inversely with the levels of LPO (rs 5 20.241, p , 0.051)
(Fig. 3). There was no significant relation between GSHPx
levels and the severity of heart failure (Table 3).
Vitamins C and E levels. The level of vitamin E did not
differ between patients with CHF and control subjects (Table
Figure 1. Relation of plasma LPO levels to heart failure functional
class.
Figure 2. Relation of plasma MDA levels to heart failure functional
class.
Table 2. Cardiac Medications in Patients in Each Functional Class
NYHA Functional Class
I (n 5 9) II (n 5 19) III (n 5 18) IV (n 5 12)
ACE inhibitor* 8 (0.89) 14 (0.74) 14 (0.78) 8 (0.67)
Diuretic agent† 4 (0.44) 16 (0.84) 16 (0.89) 10 (0.83)
Digoxin 6 (0.67) 11 (0.58) 11 (0.61) 6 (0.5)
Beta-blocker 1 (0.11) 5 (0.26) 5 (0.28) 3 (0.25)
Amiodarone 2 (0.23) 4 (0.21) 0 (0.00) 3 (0.23)
ASA 5 (0.55) 6 (0.32) 8 (0.44) 5 (0.42)
*Includes various angiotensin-converting enzyme (ACE) inhibitors. †In-
cludes loop and thiazide diuretic agents. Data are presented as number (%) of
patients. ASA 5 acetylsalicylic acid; NYHA 5 New York Heart Association.
Figure 3. Relation of plasma GSHPx activity to LPO levels.
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3). However, vitamin C levels were significantly higher in
control subjects than in patients with CHF (Table 3).
TNF-alpha, sTNF-R1 and sTNF-R2 levels. The sTNF-R1
(p , 0.005) and sTNF-R2 (p , 0.005) levels were significantly
different between control subjects and patients with CHF.
There was a rise in both sTNF-R1 and sTNF-R2 with the
functional class (sTNF-R1: rs 5 0.31, p , 0.02; TNF-R2: rs 5
0.4, p , 0.01) (Fig. 4 and 5). There was a significant correlation
between sTNF-R1 and MDA levels (rs 5 0.36, p , 0.0001),
sTNF-R2 and MDA levels (rs 5 0.514, p , 0.0002), sTNF-R1
and LPO levels (rs 5 0.313, p , 0.04) and sTNF-R2 and LPO
levels (rs 5 0.227, p , 0.05).
Discussion
Sources of oxidative stress in CHF. The formation of
LPDs, through oxidative destruction of polyunsaturated fatty
acids within cell membranes, is an important mechanism of
free radical–mediated cellular injury (28). This process is
initiated by the extraction of hydrogen atoms (H1) from
polyunsaturated fatty acids to form fatty acid radicals. These
radicals, in turn, react with oxygen to form fatty acid dioxy
radicals, which then react with other lipids and to a lesser
extent with other cell constituents (proteins, nucleic acids),
propagating the transfer of electrons (i.e., free radical forma-
tion) and perpetuating a chain reaction destructive to cell
membranes and molecules. The process ultimately terminates
in the formation of stable products such as MDA. It can also be
terminated by an enzymatic reduction of the lipid hydroperox-
ides by antioxidant enzymes such as GSHPx or by free radical
scavengers. The most important scavenger in cell membranes
is vitamin E (alpha-tocopherol); this nutritional antioxidant is
dependent on vitamin C for its regeneration (29). The gener-
ation of these products and their level in blood and tissues
(LPO and MDA) are a measure of free radical injury (28).
In the present study, we have shown a significant increase in
the plasma level of LPO and MDA in patients with CHF. The
data were similar when examined separately in patients with
ischemic cardiomyopathy (n 5 37) or dilated cardiomyopathy
(n 5 24). The increase in LPO and MDA was related to the
functional severity of heart failure, with the highest levels being
observed in patients in functional class III and IV. Only two of
our patients had renal insufficiency and three had hepatic
insufficiency; therefore, impairment of MDA and LPO metab-
olism or clearance is unlikely to have contributed to our
observations.
Our data do not show the tissue origins of the markers of
increased lipid peroxidation; both poorly perfused peripheral
muscles and the myocardium (3,30–33) could have contrib-
uted. Poor nutritional status and increased metabolic rate (34)
may also play a role. Similar to the observations of Ferrari et
al. (35), we also found a rise in both sTNF-R1 and sTNF-R2 in
relation to the functional class. Increased sTNF receptor levels
have been shown to have adverse functional consequences.
Kapadia et al. (36) have shown that these receptors modulate
the negative inotropic effect of TNF-alpha, and Ferrari et al.
(33) have shown that “sTNF-RII was a more powerful inde-
pendent indicator of mortality than TNF-alpha, sTNF-RI,
NYHA class, norepinephrine and atrial natriuretic peptide.”
In this study, we have shown a progressive rise in sTNF
receptor levels and markers of lipid peroxidation, as well as
decreased antioxidant reserves with increasing severity of
CHF. Thus, there is strong circumstantial evidence that oxida-
tive stress is a prognostic factor in CHF.
Our patients not only had evidence of increased lipid
peroxidation, but also had changes that showed that increased
lipid peroxidation in relation to functional class was of biologic
significance, because it inversely correlated with GSHPx levels
and a reduction in vitamin C. These observations in our
patients indicated that vitamin C may have been consumed to
regenerate vitamin E and that GSHPx was buffering increasing
peroxidation. Similar findings were noted in subjects with
increased peroxidation due to smoking (37); giving large doses
Figure 4. Relation of sTNF-R1 to heart failure functional class.
Figure 5. Relation of sTNF-R2 to heart failure functional class.
Table 3. Antioxidant Levels and New York Heart Association
Functional Class
Vitamin C
(mmol/liter)
Alpha-Tocopherol
(mmol/liter)
GSHPx
(U)*
Control subjects 71.4 6 3.8 11.3 6 1.0 5.4 6 0.27†‡
Patients in class I or II 63.3 6 8.4 14.2 6 1.0 4.5 6 0.2
Patients in class III or IV 61.1 6 6.8 14.3 6 0.7 4.2 6 0.2
*See Methods for definition of units. †Data previously published from our
laboratory (38). ‡p , 0.01 compared with patients with congestive heart failure.
Data are presented as mean value 6 SEM. GSHPx 5 glutathione peroxidase.
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of vitamin E increased GSHPx levels. Therefore, these data
support the possibility that in heart failure, increasing levels of
peroxidation result in a relative deficiency of antioxidant
factors.
Conclusions. Free radical injury is increased and antioxi-
dant reserves decreased in patients with CHF. This increase
correlates with functional class and with an objective marker of
prognosis—namely, sTNF receptors. These observations pro-
vide strong evidence for an adverse role of oxidative stress in
CHF and suggest that antioxidant supplementation may im-
prove myocyte function or survival, or both, and thus prove to
be an important addition to our contemporary treatment of
patients with CHF.
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